Drugs News and Research

RSS

The Wall Street Journal: Pfizer, Glaxo detail fees paid to doctors

Pfizer Inc. paid $177 million and GlaxoSmithKline PLC paid $85 million during 2010 to U.S. doctors and institutions for their work on clinical trials, consulting, speaking and other items, the companies disclosed Thursday.

1 Apr 2011

Ther-Rx Corporation announces important initiative to reduce cost of Makena

As part of its ongoing efforts to ensure that high-risk women have access to FDA-approved Makena instead of unapproved, unregulated compounded drugs, Ther-Rx Corporation, a subsidiary of K-V Pharmaceutical Company, announced today important initiatives to reduce the cost of Makena (hydroxyprogesterone caproate injection) and encourage stakeholders to provide timely access to this important FDA-approved medication.

1 Apr 2011

Geisinger expert offers advice on how to manage child's asthma

Asthma is the leading cause of hospital visits and missed school days in children, according to the National Institute of Health. A chronic condition, pediatric asthma requires continual care to prevent serious, life-threatening asthma attacks.

1 Apr 2011

Rx Partnership receives Amerigroup grant to provide Virginians with medication access

The Amerigroup Foundation today announced that it has provided a grant of $10,000 to the Rx Partnership in Richmond, Virginia. The grant will be used to support increased access to medications in four free clinics in Virginia.

1 Apr 2011

Microbix closes private financing for $0.35 per share

Microbix Biosystems Inc., a biotechnology company focused on virology and biological technologies, today announced the closing of the first tranche of a private placement resulting in the issue of 400,000 Units at a price of $0.35 per Unit.

1 Apr 2011

Insulin could play a new role in fighting Alzheimer's disease: Research

A low dose of insulin has been found to suppress the expression in the blood of four precursor proteins involved in the pathogenesis of Alzheimer's disease, according to new clinical research by University at Buffalo endocrinologists. The research, published in March online in the Journal of Clinical Endocrinology and Metabolism, suggests that insulin could have a powerful, new role to play in fighting Alzheimer's disease.

1 Apr 2011

CPRIT awards $12.6M grant to Gulf Coast Consortia to develop new cancer treatments

The Gulf Coast Consortia has been awarded a grant of more than $12.6 million from the Cancer Prevention Research Institute of Texas to launch a collaborative program that brings together researchers with the common purpose of developing new cancer treatments.

1 Apr 2011

New CMS reimbursement system for ESRD may place cost constraints on clinics

According to Millennium Research Group, the global authority on medical technology market intelligence, the new reimbursement system from the Centers for Medicare & Medicaid Services for end stage renal disease will have a mixed but mostly negative effect on the market for ESRD treatment devices.

1 Apr 2011

New lifesaving technology can combat cancer

Imagine the benefits if there was technology that pinpointed exactly which chemotherapy drugs work best in fighting each individual's type of cancer. No more guessing. No more trial and error. The good news is that such lifesaving technology is on its way to becoming reality.

1 Apr 2011

First Edition: April 1, 2011

Today's health policy news coverage helps fill in the details of the much-anticipated rule for accountable care organizations, which was released yesterday by the Obama administration.

1 Apr 2011

Broad opportunities for covalent drugs

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the publication of a scientific review article in Nature Reviews Drug Discovery titled "The Resurgence of Covalent Drugs".

1 Apr 2011

California State Controller urges Merck, Tibotec and ViiV to reduce AIDS drug prices

Today AIDS Healthcare Foundation (AHF) announced that California State Controller John Chiang has sent letters to the CEOs of Merck & Co., Tibotec Therapeutics and ViiV Healthcare, asking the companies to reduce the price of their HIV/AIDS medications for California and its AIDS Drug Assistance Program (ADAP).

1 Apr 2011

Scientists engineer new protein that prevents HIV virus entry into cells

In what could be a potential breakthrough in the battle against AIDS and a major development in the rational design of new drugs, scientists have engineered a new protein that prevents the virus from entering cells.

1 Apr 2011

Study: Stress can increase risk of C section in first-time mothers

The risk of emergency caesarean section among first-time mothers increases if the mother has experienced stress, worry, or sleep disturbances during her pregnancy. This is shown in a unique study performed collaboratively between Malmö University, Skåne University Hospital, and Lund University in Sweden.

1 Apr 2011

LIFE Biosystems to present MASE data at AACR annual meeting

Adverse events, or side effects, have traditionally been viewed as an unavoidable consequence in the therapeutic treatment of cancer patients. Yet sufficient data exists to study the relationship between molecular mechanisms, and drug-induced phenotypes to learn about - and even predict - adverse events in patients.

1 Apr 2011

New study examines psychological, social challenges of women with breast cancer

When an aggressive form of breast cancer strikes a young woman, what kind of stress, anxiety and other psychological and social challenges does she face?

1 Apr 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company's VB-111 program at the American Association for Cancer Research 102nd Annual Meeting.

1 Apr 2011

Study confirms D-penicillamine and trientine effective against Wilson disease

Results from the first ever European-wide retrospective analysis presented today at the International Liver CongressTM have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

1 Apr 2011

New data confirms antiviral activity of fluvastatin in patients with HCV

New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin -- commonly used as a cholesterol-lowering treatment -- in patients with chronic hepatitis C.

1 Apr 2011